Piericidin A
(Synonyms: 粉蝶霉素A,AR 054, Shaoguanmycin B, SN 198E) 目录号 : GC13776A potent inhibitor of mitochondrial complex I
Cas No.:2738-64-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Piericidin A is a mitochondrial complex I inhibitor.
Complex I, also known as NADH:ubiquinone oxidoreductase, catalyzes the transfer of electrons from NADH to ubiquinone as part of the respiratory chain resulting in ATP generation.
In vitro: Previous study found that piericidin A could inhibit the electron transport system at two sites. Piericidin A specifically reacted at very low concentrations at a site near the reduced NADH dehydrogenase. At high concentrations, piericidin A inhibited the succinic dehydrogenase system, and the inhibition could be partially reversed by coenzyme Q. Moreover, it was found that both the succinate and NADH oxidase system were inhibited at high levels of piericidin A [1].
In vivo: Animal study was performed to evaluate the effect of piericidin A and antagonistic effect of vitamin K3 on respiration, blood pressure and heart rate in rats. Results showed that 0.167 mg/kg of piericidin A increased the respiratory rate and the lowered blood pressure rapidly. Furthermore, vitamin K3 (10-40 mg/kg) could restore the responses to piericidin A in rats [2].
Clinical trial: Up to now, piericidin A is still in the preclinical development stage.
References:
[1] Jeng M, Hall C, Crane FL, Takahashi N, Tamura S, Folkers K. Inhibition of mitochondrial electron transport by piericidin A and related compounds. Biochemistry. 1968 Apr;7(4):1311-22.
[2] Mitsui T et al. Studies on piericidin antagonistic effect of vitamin K3 on the respiratory chain of insects and mammals in the presence of piericidin A. Agricultural and Biological Chemistry Vol. 34 (1970) No. 7 P 1101-1109
| Cas No. | 2738-64-9 | SDF | |
| 别名 | 粉蝶霉素A,AR 054, Shaoguanmycin B, SN 198E | ||
| 化学名 | 2-[(2E,5E,7E,11E)-10R-hydroxy-3,7,9R,11-tetramethyl-2,5,7,11-tridecatetraen-1-yl]-5,6-dimethoxy-3-methyl-4-pyridinol | ||
| Canonical SMILES | COC1=C(O)C(C)=C(C/C=C(C)/C/C=C/C(C)=C/[C@H]([C@@H](O)/C(C)=C/C)C)N=C1OC | ||
| 分子式 | C25H37NO4 | 分子量 | 415.6 |
| 溶解度 | Soluble in DMSO, Soluble in DMF, Soluble in Ethanol, Soluble in Methanol | 储存条件 | Store at -80°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4062 mL | 12.0308 mL | 24.0616 mL |
| 5 mM | 0.4812 mL | 2.4062 mL | 4.8123 mL |
| 10 mM | 0.2406 mL | 1.2031 mL | 2.4062 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet